Olive JF, Qin Y, DeCristo MJ, Laszewski T, Greathouse F, McAllister SS. Accounting for tumor heterogeneity when using CRISPR-Cas9 for cancer progression and drug sensitivity studies. PLoS One. 2018;13(6):e0198790. doi:10.1371/journal.pone.0198790
Gupta RM, Hadaya J, Trehan A, et al. A Genetic Variant Associated with Five Vascular Diseases Is a Distal Regulator of Endothelin-1 Gene Expression. Cell. 2017;170(3):522-533.e15. doi:10.1016/j.cell.2017.06.049
Tang W, Liu DR. Rewritable multi-event analog recording in bacterial and mammalian cells. Science. 2018;360(6385). doi:10.1126/science.aap8992
Dharia NV, Kugener G, Guenther LM, et al. A first-generation pediatric cancer dependency map. Nat Genet. 2021;53(4):529-538. doi:10.1038/s41588-021-00819-w
Santos DP, Kiskinis E, Eggan K, Merkle FT. Comprehensive Protocols for CRISPR/Cas9-based Gene Editing in Human Pluripotent Stem Cells. Curr Protoc Stem Cell Biol. 2016;38:5B.6.1-5B.6.60. doi:10.1002/cpsc.15
Aguirre AJ, Meyers RM, Weir BA, et al. Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting. Cancer Discov. 2016;6(8):914-29. doi:10.1158/2159-8290.CD-16-0154
Rosenbluh J, Mercer J, Shrestha Y, et al. Genetic and Proteomic Interrogation of Lower Confidence Candidate Genes Reveals Signaling Networks in β-Catenin-Active Cancers. Cell Syst. 2016;3(3):302-316.e4. doi:10.1016/j.cels.2016.09.001